References
- David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. In: Fortson EA, Feldman SR, Strowd LC, editors. Management of atopic dermatitis: methods and challenges. Cham: Springer International Publishing; 2017. p. 21–37.
- Furue M, Chiba T, Tsuji G, et al. Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol Int. 2017;66(3):398–403.
- Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878.
- Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
- Regeneron Pharmaceuticals and Sanofi Genzyme. Regeneron Pharmaceuticals and Sanofi Genzyme. Dupixent (Dupilumab) package insert. U.S. Food and Drug Administration website [Internet]. [cited 2019. Jul 16]. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf
- Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
- Kerdel F, Zaiac M. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol Ther. 2015;28(6):390–403.
- Hamawy MM. Molecular actions of calcineurin inhibitors. Drug News Perspect. 2003;16(5):277–282.
- Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7(1):1–23.
- Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema – a systematic review and meta-analysis. J Eur Acad Dermatol Venerol. 2007;21:606–619.
- Granlund H, Erkko P, Sinisalo M, et al. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol. 1995;132(1):106–112.
- Mrowietz U, de Jong E, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014;28(4):438–453.
- Craig A, Elmets MD. Recommendations for transitioning and combinations of medications in moderate to severe psoriasis. NEJM Journal Watch [Internet]. 2013. [cited 2019 Jul 13]. Available at https://www.jwatch.org/JD201304050000001/2013/04/05/recommendations-transitioning-and-combinations
- Psoriasis (SIMPSO) SIM nella. Management of Erythrodermic Psoriasis with Low-Dose Cyclosporin. DRM. 1993;187:30–37.
- Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86(3):301–307.
- Lyakhovitsky A, Barzilai A, Heyman R, et al. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol. 2010;24(1):43–49.
- Dhir V, Sandhu A, Kaur J, et al. Comparison of two different folic acid doses with methotrexate–a randomized controlled trial (FOLVARI Study). Arthritis Res Ther. 2015;17(1):156.
- DAVA Pharmaceuticals, Inc. Methotrexate. U.S. Food and Drug Administration website [Internet]. [Cited 2016 01] Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008085s066lbl.pdf
- The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy [Internet]. [cited 2019 Jul 27]. Available at http://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-0511
- Liu Y, Zhou S, Nissel J, et al. The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis. Clin Pharm Drug Dev. 2014;3(6):456–465.
- Neuber K, Schwartz I, Itschert G, et al. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol. 2000;143(2):385–391.
- Murray ML, Cohen JB. Mycophenolate mofetil therapy for moderate to severe atopic dermatitis. Clin Exp Dermatol. 2007;32:23–27.
- Roche. CellCept (Mycophenolate Mofetil) package insert. U.S. Food and Drug Administration website. [Internet]. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050722s021,050723s019,050758s019,050759s024lbl.pdf
- Biot S, Franco JP, de A, Lima RB, et al. Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil. An Bras Dermatol. 2014;89(6):980–984.
- Lee DE, Clark AK, Tran KA, et al. New and emerging targeted systemic therapies: a new era for atopic dermatitis. J Dermatol Treat. 2018;29(4):364–374.
- Hendricks AJ, Lio PA, Shi VY. Management recommendations for dupilumab partial and non-durable responders in atopic dermatitis. Am J Clin Dermatol. 2019;20(4):565.